These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 15745203)

  • 21. Use of naltrexone in treating opioid use disorder in pregnancy.
    Towers CV; Katz E; Weitz B; Visconti K
    Am J Obstet Gynecol; 2020 Jan; 222(1):83.e1-83.e8. PubMed ID: 31376396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs methadone.
    Oliveto AH; Feingold A; Schottenfeld R; Jatlow P; Kosten TR
    Arch Gen Psychiatry; 1999 Sep; 56(9):812-20. PubMed ID: 12884887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use and misuse of opioid agonists in opioid addiction.
    Modesto-Lowe V; Swiezbin K; Chaplin M; Hoefer G
    Cleve Clin J Med; 2017 May; 84(5):377-384. PubMed ID: 28530896
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Addiction disorders.
    Merrill JO; Duncan MH
    Med Clin North Am; 2014 Sep; 98(5):1097-122. PubMed ID: 25134875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of opioid antagonists in treating intravenous cocaine abuse.
    Kosten TR; Kleber HD; Morgan C
    Life Sci; 1989; 44(13):887-92. PubMed ID: 2927249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.
    Johnson RE; Chutuape MA; Strain EC; Walsh SL; Stitzer ML; Bigelow GE
    N Engl J Med; 2000 Nov; 343(18):1290-7. PubMed ID: 11058673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
    Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N
    J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacological interventions for drug-using offenders.
    Perry AE; Neilson M; Martyn-St James M; Glanville JM; Woodhouse R; Godfrey C; Hewitt C
    Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD010862. PubMed ID: 26035084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Update on the clinical use of buprenorphine: in opioid-related disorders.
    Ducharme S; Fraser R; Gill K
    Can Fam Physician; 2012 Jan; 58(1):37-41. PubMed ID: 22267618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The pharmacological treatment of opioid addiction--a clinical perspective.
    Lobmaier P; Gossop M; Waal H; Bramness J
    Eur J Clin Pharmacol; 2010 Jun; 66(6):537-45. PubMed ID: 20169438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Understanding and co-managing medication treatment options for opioid use disorder.
    Kay A; Shmuts R; Beck M
    Intern Emerg Med; 2022 Oct; 17(7):2159-2165. PubMed ID: 35138549
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Consumer attitudes about opioid addiction treatment: a focus group study in New York City.
    Sohler NL; Weiss L; Egan JE; López CM; Favaro J; Cordero R; Cunningham CO
    J Opioid Manag; 2013; 9(2):111-9. PubMed ID: 23709320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Messages about methadone and buprenorphine in reality television: a content analysis of celebrity rehab with Dr. Drew.
    Roose R; Fuentes L; Cheema M
    Subst Use Misuse; 2012 Aug; 47(10):1117-24. PubMed ID: 22587811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure.
    Shulman M; Choo TH; Scodes J; Pavlicova M; Wai J; Haenlein P; Tofighi B; Campbell ANC; Lee JD; Rotrosen J; Nunes EV
    J Subst Abuse Treat; 2021 May; 124():108292. PubMed ID: 33771287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Addiction pharmacotherapy 2000: new options, new challenges.
    Rawson RA; McCann MJ; Hasson AJ; Ling W
    J Psychoactive Drugs; 2000; 32(4):371-8. PubMed ID: 11210198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prescription opioid use, misuse, and diversion among street drug users in New York City.
    Davis WR; Johnson BD
    Drug Alcohol Depend; 2008 Jan; 92(1-3):267-76. PubMed ID: 17913395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Systematic Review on the Use of Psychosocial Interventions in Conjunction With Medications for the Treatment of Opioid Addiction.
    Dugosh K; Abraham A; Seymour B; McLoyd K; Chalk M; Festinger D
    J Addict Med; 2016; 10(2):93-103. PubMed ID: 26808307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index.
    Strain EC; Stitzer ML; Liebson IA; Bigelow GE
    J Clin Psychopharmacol; 1996 Feb; 16(1):58-67. PubMed ID: 8834420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial.
    Sees KL; Delucchi KL; Masson C; Rosen A; Clark HW; Robillard H; Banys P; Hall SM
    JAMA; 2000 Mar; 283(10):1303-10. PubMed ID: 10714729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.